ClinicalTrials.gg
Not yet recruitingNCT07853989Updated Nov 12, 2026

Effect of TMS Treatment on Defense Mechanisms and Functionality in Patients With Depression

An observational study in Major Depressive Disorder (MDD), sponsored by Namik Kemal University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Namik Kemal University · Observational

How we know

Updated Nov 12, 2026Start date movedEligibility revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Depressive Disorder, Major with a site in Turkey — 14 open to participants now, 15 under way, 1 of them phase 3. Depressive Disorder, Major · Turkey.

Started
2026
with 6 others
Observational
8 of 32
7 open now
Primary completion
2027-04
later than 10 of 14 live
Registered
30th of 32
by date

Among the 32 studies in Depressive Disorder, Major with a site in Turkey, this one is one of 7 that started in 2026, is one of 8 observational ones, reaches primary completion later than 10 of the 14 other live ones, and was the 30th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

14 of the 32 studies in Depressive Disorder, Major with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Depressive Disorder, Major with a site in Turkey, or all of them as a file.
02

Study summary

This prospective observational study aims to evaluate changes in psychological defense mechanisms in patients with non-psychotic major depressive disorder (MDD) undergoing repetitive Transcranial Magnetic Stimulation (rTMS) therapy. The study investigates whether rTMS induces a shift from immature to more mature defense mechanisms and assesses how these changes relate to improvements in depressive symptom severity, anxiety levels, and overall functionality at baseline, 1-month, and 3-month follow-ups.

Read the detailed description

Major depressive disorder (MDD) significantly impacts mood, cognitive function, and psychological defense structures. While repetitive Transcranial Magnetic Stimulation (rTMS) is an established non-invasive neuromodulation therapy for depression, its influence on psychodynamic constructs such as defense mechanisms remains insufficiently explored.

This single-center prospective study will enroll 50 adult participants (aged 18-65) diagnosed with non-psychotic MDD according to DSM-5 criteria (confirmed via SCID-5). Participants will receive rTMS treatment as part of their standard clinical care. Clinical assessments will be conducted by a blinded researcher at three time points: baseline (pre-treatment), 1 month, and 3 months post-baseline.

Primary outcomes will measure shifts in defense mechanism styles (mature, neurotic, immature) using the Defense Style Questionnaire (DSQ). Secondary outcomes will assess depressive symptom severity (Hamilton Depression Rating Scale - HAM-D), anxiety levels (Hamilton Anxiety Rating Scale - HAM-A), clinical severity and improvement (Clinical Global Impression Scale - CGI), and functional impairment (World Health Organization Disability Assessment Schedule 2.0 - WHODAS 2.0).

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • TMS
  • Transcranial Magnetic Stimulation
  • Defense Mechanisms
  • depression
  • functionality
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18-65 years with non-psychotic major depressive disorder (MDD) who are evaluated for suitability for transcranial magnetic stimulation (TMS) treatment at the Psychiatry Clinic/TMS Unit of Tekirdağ Namık Kemal University Hospital. The diagnosis of MDD will be confirmed using the Structured Clinical Interview for DSM Disorders (SCID). Approximately 50 participants who meet the eligibility criteria and provide written informed consent will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Diagnosis of major depressive disorder without psychotic features according to criteria
  • Confirmation of diagnosis via SCID
  • Major depressive disorder as the primary reason for admission
  • Willingness to participate and signing the written form

Exclusion criteria

Exclusion Criteria:

  • Presence of for TMS (e.g., metallic implants)
  • Known active psychotic symptoms
  • History of TMS treatment in the past 3 months
  • Presence of known organic brain syndrome, neurological, or major systemic medical conditions
  • Presence of known intellectual disability or significant cognitive impairment
  • Active substance or alcohol use disorder
  • Illiteracy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • TMS Treatment Group

    Patients diagnosed with major depressive disorder receiving Transcranial Magnetic Stimulation therapy.

06

What researchers measure

Primary outcomes

  1. Change in Defense Mechanisms (Defense Style Questionnaire - DSQ)

    Evaluates shifts in mature, neurotic, and immature psychological defense mechanism styles in patients with major depressive disorder following TMS treatment.

    Time frame: Baseline, 1 month, and 3 months

Secondary outcomes

  1. Change in Anxiety Symptom Severity (Hamilton Anxiety Rating Scale - HAM-A)

    Assesses psychic and somatic anxiety symptom severity.

    Time frame: Baseline, 1 month and 3 months

  2. Change in Depressive Symptom Severity (Hamilton Depression Rating Scale - HAM-D)

    Assesses the severity of depressive symptoms

    Time frame: Baseline, 1 month, and 3 months

  3. Change in Clinical Global Impression (CGI)

    Measures overall illness severity and clinical improvement.

    Time frame: Baseline, 1 month, and 3 months

  4. Change in Disability and Functionality (World Health Organization Disability Assessment Schedule 2.0 - WHODAS 2.0)

    Evaluates level of functional disability across six domains (understanding/communicating, mobility, self-care, getting along, life activities, participation).

    Time frame: Baseline, 1 month, and 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.

Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 4 months is below that.

Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Dec 1, 2026was Oct 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Dec 1, 2026
Nov 12, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedConfirmation of diagnosis via SCID-5
Oct 13, 2026
Interventions
Arms or interventions changed
Oct 13, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedChange in Disability and Functionality (World Health Organization Disability Assessment Schedule 2.0 - WHODAS 2.0)Time frame: Baseline, 1 month, and 3 months
Oct 13, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedChange in Disability and Functionality (World Health Organization Disability Assessment Schedule 2.0 - WHODAS 2.0)Time frame: Baseline, 1 month, and 3 months
Oct 13, 2026
Design
Study type Interventional→Observational
Oct 13, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Nov 12, 2026
    Start date Oct 1, 2026→Dec 1, 2026
    + 1 other change: verification date
  2. Oct 13, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedConfirmation of diagnosis via SCID-5
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedChange in Disability and Functionality (World Health Organization Disability Assessment Schedule 2.0 - WHODAS 2.0)Time frame: Baseline, 1 month, and 3 months
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedChange in Disability and Functionality (World Health Organization Disability Assessment Schedule 2.0 - WHODAS 2.0)Time frame: Baseline, 1 month, and 3 months
    Interventions Arms or interventions changed
    Design Study type Interventional→Observational
    + 2 other changes: index terms and verification date
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853989
Lead sponsor
Namik Kemal University
Responsible party
Kardelen Erdoğan (Research Assistant, Namik Kemal University) — Principal investigator
First posted
Oct 2, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Kardelen Erdoğan, MD
Contact
kardelenerdogan@nku.edu.tr
+90 543 691 87 52

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion